Abstract

Bayer A.G. will report quarterly results on August 4, 2026 after market close; this preview reviews prior-quarter performance, synthesizes current-quarter forecasts on revenue, margin, net income, and adjusted EPS, and incorporates market commentary on business drivers and litigation updates.

Market Forecast

Consensus for the current quarter points to revenue of 12.31 billion US dollars, an estimated year-over-year decline of 4.47%, with estimated EPS of 0.25 and EBIT of 1.33 billion US dollars, implying year-over-year growth of 7.53% for EBIT and flat year-over-year for EPS; company-level margin guidance is not specified, but recent run-rate suggests investors are watching gross margin sustainability and net margin resilience alongside adjusted EPS trends. Crop Science remains the primary revenue engine, while Pharmaceuticals and Consumer Health provide diversification; the outlook centers on pricing normalization in herbicides offset by disciplined cost control and product mix improvement. The most promising growth lever is Women’s Health within Consumer Health, supported by the long-acting reversible contraception portfolio that has maintained double-digit sales growth in recent years; revenue contribution last quarter was 1.49 billion US dollars, and expansion plans backed by a 3 billion euro strategic investment are expected to underpin continued momentum.

Last Quarter Review

Bayer A.G.’s previous quarter delivered revenue of 15.69 billion US dollars, a gross profit margin of 60.97%, net profit attributable to shareholders of 2.76 billion US dollars with a net profit margin of 20.61%, and adjusted EPS of 0.73, with revenue up 8.50% year over year and adjusted EPS up 10.67% year over year. Net income rose sharply on a sequential basis, with quarter-on-quarter growth of 173.54%, reflecting favorable mix and operational execution. Main business performance showed Crop Science at 7.56 billion US dollars, Pharmaceuticals at 4.25 billion US dollars, and Consumer Health at 1.49 billion US dollars; within agriculture, pricing normalization in glyphosate continued even as operational efficiency supported profitability, and Consumer Health maintained steady demand in core categories.

Current Quarter Outlook

Main business: Crop Science demand normalization, pricing reset, and cost discipline

The market expects Crop Science to remain the largest revenue contributor in the quarter, though top-line pressure persists in herbicides as glyphosate pricing continues to normalize. Against this backdrop, management emphasis on cost efficiency and product mix is critical for margin preservation. Seed and traits, along with selective crop protection categories beyond glyphosate, are expected to provide partial offsets as channel inventories normalize and the Northern Hemisphere season progresses. The implied revenue decline at the group level suggests Crop Science volumes and pricing will be more subdued than the prior quarter, but EBIT guidance for the group implies operating leverage from cost control is still expected to contribute. Investors will parse qualitative commentary for signs of stabilization in herbicides, order pace in Latin America ahead of the planting season, and the cadence of price/mix in seeds to gauge the likelihood of margin durability through the back half of the year.

Most promising business: Women’s Health and Consumer Health innovation cycle

Consumer Health, and specifically Women’s Health, is positioned as a bright spot, with the long-acting reversible contraception franchise supported by a new 3 billion euro strategic investment structure designed to strengthen balance sheet flexibility while retaining operational control. Last quarter, Consumer Health contributed 1.49 billion US dollars, and the LARC portfolio has maintained double-digit sales growth in recent years, offering a resilient, cash-generative counterweight to cyclicality in crop inputs. The transaction design, with minority, non-controlling capital participation, preserves strategic direction and accelerates resource deployment across manufacturing capacity and market access, potentially supporting steady mid-term revenue growth. In the near term, focus will be on demand elasticity, geographic uptake, and the pace at which incremental investment translates into volume availability and brand penetration.

Stock price swing factors this quarter: litigation trajectory, pipeline milestones, and operating leverage

Headline sensitivity remains elevated around the herbicide litigation trajectory in the United States, where recent developments included a favorable U.S. Supreme Court decision overturning an adverse verdict and, separately, procedural shifts that have pressured sentiment; any incremental clarity on the settlement framework and appeals could influence multiple expansion or compression. Pipeline milestones, including regulatory progress for renal and cardiovascular assets such as the Kerendia label expansion under U.S. FDA priority review for type 1 diabetes-related chronic kidney disease, could support Pharmaceuticals’ narrative and underpin medium-term earnings quality. Operating leverage is the third near-term swing factor: with revenue estimated to decline year over year, the degree to which cost control and mix can sustain EBIT growth will be central to valuation; management color on gross-to-net dynamics, procurement savings, and manufacturing footprint optimization is likely to shape the stock’s post-report reaction.

Analyst Opinions

Across recent institutional commentary and market-facing summaries, the majority stance is constructive, with broadly positive views outnumbering cautious takes by approximately 4:1 in our collected set. Bullish arguments highlight the strengthening cash-generation profile from Consumer Health, the stabilizing arc in Crop Science as channel inventories normalize, and the incremental de-risking from favorable litigation developments. Commentary also calls out the supportive read-through from an external 3 billion euro investment in the Women’s Health franchise and the prospect that EBIT can grow year over year despite a revenue decline, reflecting mix and cost execution. The prevailing view anticipates that management’s update on herbicide pricing normalization, combined with visibility on the Pharmaceuticals pipeline cadence, will anchor sentiment into the second half, while acknowledging that legal headlines can still drive volatility around the print.